" 今年两块投入或达大几十亿元。 " 作者丨应梅 编辑丨代聪飞 发布2024年Q4及全年财报后，美团释放了两个今年将重点投入的方向： 出海、AI。 出海业务的花费首次较为明显地体现在2024年Q4财报中。在优选等新业务持续减亏的情况下，美团新业 务Q4环比Q3，新增了12亿元亏损。当然，全年来看新业务在2024年大幅减亏，相比2023年依然减亏超 百亿元。 多位投资者表示，出海亏损还在预期之内。从过去2024年的业绩来看，美团并不打算牺牲利润去做出海业 务的投入。而是相对谨慎地扩张。 知情人士向雷峰网表示， 当初做香港市场美团考察了很久，做沙特市场美团也准备了两年。 2023年5月 美团外卖国际版Keeta在香港上线后，时隔一年半，于2024年10月上线沙特首都利雅得。当下出海有了 一些新进展，已经确定在中东市场更多国家扩张。 3月21日晚的财报电话会上，美团CEO王兴谈了十几分钟AI，首次较为详细谈论美团的AI布局和进展。美 团过去一年GPU资源投入达数十亿元。王兴进一步释放信号，今年会加大这方面的资本支出。了解更多美 团出海和AI投入的信息，欢迎添加微信 zymcfip 交流~ GPT3.5问世两年以来， ...

Summary of the Conference Call for Boya Biological Company Overview - **Company**: Boya Biological - **Focus**: Blood products, with a strategic emphasis on expanding production and market presence Key Points and Arguments Financial Performance - **Total Revenue**: 1.735 billion CNY, a year-on-year decrease primarily due to the divestiture of Tianan Pharmaceutical and Fudan Pharmaceutical [3] - **Blood Products Revenue**: 1.514 billion CNY, a year-on-year increase of 4.32%, driven by significant sales growth in prothrombin complex and factor VIII [3] - **Operating Profit**: 397 million CNY, a year-on-year increase of 67.18%, attributed to a lower base from the previous year [3] - **Return on Equity**: Increased by 2.08 percentage points to 5.36% [3] Business Expansion and Acquisitions - **Acquisition**: Successfully acquired 100% of the shares of Roche in Hong Kong, adding a production license and four plasma collection stations, bringing the total to 21 stations across seven provinces [5] - **Plasma Collection**: Achieved 630.6 tons of plasma collection, a year-on-year increase of 10.4%, with the main collection unit growing by 11.7%, surpassing industry averages [5] Product Development and Market Strategy - **Product Sales**: Strong performance in fibrinogen, with PCC and factor VIII exceeding sales targets, and PCC holding the third-largest market share [6] - **International Expansion**: Registered a new immunoglobulin product in Pakistan, indicating a strategic move towards international markets [6] Major Projects - **Smart Factory Project**: Progressing as planned, with the main structure completed and equipment installation ongoing, expected to commence production by the end of 2025, with financial impacts anticipated post-2027 [7][15] Industry Dynamics - **Supply and Demand**: Industry supply pressures have eased, with balanced demand for protein products, although competition for factor products may intensify [10] - **Collective Procurement Strategy**: Actively participating in Guangdong's collective procurement, monitoring policy changes closely [10] Future Projections - **Plasma Collection Goals for 2025**: Expected to exceed 700 tons, with a growth rate of over 10% [3][17] - **New Product Launches**: Anticipated rapid market uptake for new products expected to launch in Q3 2025 [9] Regulatory and Market Considerations - **Regulatory Changes**: Ongoing discussions regarding potential revisions to blood product management regulations, which could significantly impact the industry [20] - **Market Strategy Adjustments**: Focus on regional market penetration, particularly in East China, to optimize existing production capacity [21] Integration and Collaboration - **Sales Team Integration**: Ongoing integration of sales teams from Roche and Boya, aiming for enhanced market coverage and synergy [19] - **Technical Collaborations**: Engaging in technical cooperation with Central Asian countries to expand market reach and capabilities [17] Investment and Future Outlook - **Investment Plans**: Continued focus on core business and strategic acquisitions to enhance market position and operational efficiency [24] - **Long-term Growth Strategy**: Emphasis on technological innovation and market competitiveness to ensure sustainable growth [26] Additional Important Insights - **Market Potential in New Regions**: Significant growth potential identified in Anhui and Inner Mongolia, with strategic plans to address local concerns and enhance operational trust [22] - **Impact of Economic Conditions**: Despite macroeconomic pressures, the company has maintained a strong performance trajectory [11]